Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Moore

Showing results (1361-1370 of 1,421) with videos related to

Pageof 143
Sort By:
JCI Insight|April 28, 2021
Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus macaquesYongjun Sui, Jianping Li, Roushu Zhang, et al.
Future Oncology (London, England)|June 19, 2023
ARTISTRY-7: phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancerThomas J Herzog, John L Hays, Joyce N Barlin, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2026
Overcoming host immune responses to an AAV-delivered HIV-1 bNAb in rhesus macaques mediated by co-delivery of PD-L1Michael Kuipa, Abubakarr A Koroma, Isai Leguizamo, et al.
Nature Communications|April 20, 2021
Phenological shifts in lake stratification under climate changeR Iestyn Woolway, Sapna Sharma, Gesa A Weyhenmeyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2025
Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201Susana N Banerjee, Els Van Nieuwenhuysen, Carol Aghajanian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 23, 2021
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)Kathleen N Moore, Michael Bookman, Jalid Sehouli, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2026
Co-delivered PD-L1 rescues the protective efficacy mediated by an AAV-expressed HIV-1 bNAbMichael Kuipa, Abubakarr A Koroma, Isai Leguizamo, et al.
JAMA Oncology|June 14, 2019
Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian CarcinomaPanagiotis A Konstantinopoulos, Steven Waggoner, Gregory A Vidal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2025
Molecular profiling and tumour biomarker analysis of GOG281/LOGS: a positive late-phase trial of trametinib for recurrent/persistent low grade-serous ovarian cancerRobert L Hollis, Austin Miller, Heather A Lankes, et al.
Nature Communications|November 20, 2025
Sex-specific role of the 5-HT<sub>2A</sub> receptor in psilocybin-induced extinction of opioid rewardAlaina M Jaster, Thomas M Hadlock, Belle Buzzi, et al.
Pageof 143

Showing results (1361-1370 of 1,421) with videos related to

Sort By:
Pageof 143
JCI Insight|April 28, 2021
Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus macaquesYongjun Sui, Jianping Li, Roushu Zhang, et al.
Future Oncology (London, England)|June 19, 2023
ARTISTRY-7: phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancerThomas J Herzog, John L Hays, Joyce N Barlin, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2026
Overcoming host immune responses to an AAV-delivered HIV-1 bNAb in rhesus macaques mediated by co-delivery of PD-L1Michael Kuipa, Abubakarr A Koroma, Isai Leguizamo, et al.
Nature Communications|April 20, 2021
Phenological shifts in lake stratification under climate changeR Iestyn Woolway, Sapna Sharma, Gesa A Weyhenmeyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2025
Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201Susana N Banerjee, Els Van Nieuwenhuysen, Carol Aghajanian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 23, 2021
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)Kathleen N Moore, Michael Bookman, Jalid Sehouli, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2026
Co-delivered PD-L1 rescues the protective efficacy mediated by an AAV-expressed HIV-1 bNAbMichael Kuipa, Abubakarr A Koroma, Isai Leguizamo, et al.
JAMA Oncology|June 14, 2019
Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian CarcinomaPanagiotis A Konstantinopoulos, Steven Waggoner, Gregory A Vidal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2025
Molecular profiling and tumour biomarker analysis of GOG281/LOGS: a positive late-phase trial of trametinib for recurrent/persistent low grade-serous ovarian cancerRobert L Hollis, Austin Miller, Heather A Lankes, et al.
Nature Communications|November 20, 2025
Sex-specific role of the 5-HT<sub>2A</sub> receptor in psilocybin-induced extinction of opioid rewardAlaina M Jaster, Thomas M Hadlock, Belle Buzzi, et al.
Pageof 143